Biosimilar Antibody-Drug Conjugates? Pfizer Isn’t Banking On It
‘The Regulatory Path Has To Be Determined. It Doesn’t Exist Today’
Executive Summary
Pfizer’s $43bn agreement to acquire Seagen would layer its portfolio and pipeline with vastly complex antibody-drug conjugates – a class of drug that both parties feel might be almost immune to biosimilar competition.
You may also be interested in...
Pfizer Pays $43bn For Seagen With Goal Of Rapidly, Globally Advancing ADCs
Pfizer expects its acquisition of Seagen to result in $10bn in new revenue by 2030 as the big pharma applies its resources to the target company’s pioneering antibody-drug conjugate technology.
Hybrid Specialist Azurity Snaps Up Complex Generics Firm Slayback Pharma
In an acquisition said by both US-based companies to be highly complementary, Azurity Pharmaceuticals has taken control of Slayback Pharma for an undisclosed fee.
US Court Says Yes To Gilead’s Quarter Billion Dollar Settlement On Truvada, Atripla
Despite winning a landmark multi-billion-dollar antitrust suit earlier this year, Gilead Sciences has seen a US court give an initial green light allowing it to shell out nearly $250m to settle antitrust claims from direct purchasers of its two major HIV drugs.